Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vor Biopharma Inc. (Vor Bio) SEC filings page on Stock Titan provides streamlined access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer trading under the symbol VOR, Vor Bio reports on its clinical-stage biotechnology business focused on telitacicept, a dual BAFF/APRIL fusion protein being developed for serious autoimmune diseases.
Through this page, readers can review current and historical filings such as Forms 10‑K and 10‑Q for detailed discussions of risk factors, financial condition, and the status of telitacicept clinical programs, along with Form 8‑K reports describing material events. Recent 8‑K filings have covered topics including underwritten public offerings of common stock, a private placement with institutional investors, a reverse stock split, changes to equity incentive plans, and governance updates involving Board and executive appointments.
Vor Bio also uses 8‑K filings to furnish investor presentations and clinical data updates, for example webcasts and slide decks discussing late-breaking Phase 3 results for telitacicept in Sjögren’s disease and IgA nephropathy, as well as global development plans in generalized myasthenia gravis. Other filings, such as proxy statements (DEF 14A), describe stockholder proposals related to equity plans, warrant issuances, and capital structure changes.
On Stock Titan, these documents are complemented by AI-powered summaries that highlight key points from lengthy filings, helping users quickly understand how new financings, clinical milestones, or corporate actions may affect Vor Bio’s capital structure and development strategy. Investors can also locate information related to registered offerings on Form S‑3, at‑the‑market sales programs, and other registration statements referenced in the company’s 8‑K disclosures. This page is designed to make it easier to follow the regulatory record behind VOR, from financial reporting to telitacicept’s progress through late-stage development.
Vor Biopharma Inc. (VOR) reported a non-derivative/derivative reporting event showing a 60,000-share stock option granted on 09/08/2025 with a $1.98 exercise price. The option is held for the benefit of RA Capital funds and is reported as indirect ownership of 60,000 shares, subject to monthly vesting in 36 equal installments beginning 09/08/2025 and with an indicated exercisability/expiration date of 09/07/2035. Reporting entities include RA Capital Management, L.P., RA Capital Healthcare Fund, RA Capital Nexus Fund, and individuals Dr. Peter Kolchinsky and Rajeev Shah, who disclaim beneficial ownership except for pecuniary interests. Ms. Sarah Reed, General Counsel of the Adviser, serves on Vor's board and will hold the option for the benefit of the funds under an arrangement requiring turnover of any net proceeds to offset advisory fees.
Vor Biopharma Inc. director Sarah Burgess Reed was granted a stock option on 09/08/2025 to purchase 60,000 shares of common stock at an exercise price of $1.98 per share. The option vests in 36 equal monthly installments beginning on the grant date and is exercisable through 09/07/2035. The filing notes Ms. Reed holds the option for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P., and she disclaims beneficial ownership because any net proceeds will be turned over to the adviser to offset advisory fees. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/10/2025.
Amendment No. 2 to Schedule 13D discloses that Reprogrammed Interchange LLC and Reid Hoffman collectively beneficially own 35,476,939 shares of Vor Biopharma Inc., representing 28.0% of the outstanding common stock. The amendment reports open-market sales by Reprogrammed Interchange LLC from August 25, 2025 through September 5, 2025 that reduced the reporting persons' stake by more than one percentage point. Recent dispositions total 3,497,162 shares sold in multiple transactions at weighted average prices around $2.00 per share. The filing amends prior Schedule 13D disclosures and otherwise leaves earlier statements unchanged.
Vor Biopharma Inc. (VOR) filing an initial Form 3 by reporting person Sarah Burgess Reed shows she is identified as a director and that, as of the event date 08/27/2025, no securities are beneficially owned by her. The filing is marked as an initial statement and was signed on 09/08/2025 by an attorney-in-fact, Sherell Bacchas.
This is a routine Section 16 disclosure showing the reporting relationship and a declaration of zero ownership of the issuer's equity. The form does not report any derivative holdings, purchases, sales, or other transactions and contains no financial tables or material transaction details.
Vor Biopharma Inc. (VOR) Form 4: Reprogrammed Interchange LLC and Reid Hoffman reported a series of open-market sales of common stock in early September 2025. Reprogrammed sold 554,612 shares on 09/03/2025 at a weighted average price of $1.9961, 453,016 shares on 09/04/2025 at $1.9285, and 400,000 shares on 09/05/2025 at $1.9682. Following these transactions, Reprogrammed's reported beneficial ownership decreased from 36,329,955 shares to 35,476,939 shares. The filing notes that Reid Hoffman may be deemed a beneficial owner of shares held by Reprogrammed but disclaims ownership except for pecuniary interest.
Vor Biopharma Inc. Form 144 notifies the market that a person identified as Audrey Skillern intends to sell 23,000,000 common shares on or about 09/03/2025 on NASDAQ. The filing lists an aggregate market value of $46,115,000 for the shares and reports 126,683,111 shares outstanding for the issuer.
The shares were acquired from the company in a private placement on 12/26/2024 and fully paid in cash on that date. The filer reports no securities sold in the past three months. The notice includes the required representation that the seller is not aware of undisclosed material adverse information about the issuer.
Vor Biopharma Inc. furnished a new corporate presentation to the investment community, dated September 2025, and made it available on its website. The materials are provided under Item 7.01 of a current report and are attached as Exhibit 99.1. The company notes that this information, including Exhibit 99.1, is being furnished rather than filed under the securities laws and will only be incorporated into other filings if specifically referenced.
Amendment No. 1 to a Schedule 13D discloses that Reprogrammed Interchange LLC and Reid Hoffman together beneficially own 36,884,567 shares of Vor BioPharma Inc., representing 29.1% of the outstanding Common Stock. The amendment reports open-market sales by Reprogrammed Interchange LLC from August 25–28, 2025, totaling 2,089,534 shares. Reported weighted-average sale prices were $2.1163 on August 25, $2.0808 on August 26, $2.0053 on August 27 and $2.0115 on August 28. The filing states these sales reduced the Reporting Persons' holdings by more than one percent of the outstanding shares and otherwise incorporates prior Schedule 13D disclosures.
Vor Biopharma insider report: Reprogrammed Interchange LLC sold common stock on 08/27/2025 and 08/28/2025, and the report lists Reid Hoffman as a person who may be deemed a beneficial owner of shares held by Reprogrammed. The entity sold 611,647 shares on 08/27/2025 at a weighted average price of $2.0053 and sold 806,351 shares on 08/28/2025 at a weighted average price of $2.0115. After the 08/27 trades, Reprogrammed beneficially owned 37,690,918 shares; after the 08/28 trades it reported 36,884,567 shares. The filings state the 08/27 sales ranged from $1.99 to $2.10 and the 08/28 sales ranged from $1.95 to $2.075, and that full trade-level information will be provided upon request. The Form 4 is signed by Frank Huang as manager of Reprogrammed Interchange LLC and by Reid Hoffman, each dated 08/29/2025.
Reprogrammed Interchange LLC, an entity associated with Reid Hoffman, reported sales of common stock of Vor Biopharma Inc. (VOR) on August 25-26, 2025. The filing shows 387,346 shares sold on 08/25/2025 at a weighted average price of $2.1163, and 284,190 shares sold on 08/26/2025 at a weighted average price of $2.0808. Following the 08/25 sale the filing reports 38,586,755 shares beneficially owned by Reprogrammed and after the 08/26 sale 38,302,565 shares were reported.
The filer states the shares are held by Reprogrammed Interchange LLC and that Reid Hoffman may be deemed a beneficial owner by virtue of shared control and indirect pecuniary interest, while disclaiming beneficial ownership except to the extent of his pecuniary interest. The transactions were signed on 08/27/2025 by Frank Huang, Manager of Reprogrammed Interchange LLC, and Reid Hoffman.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
